Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJason Sperry

About this trial

The Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) trial will be a 6-year (4-year enrollment), open label, phase-3, multi-center, early in-hospital phase randomized trial utilizing burn centers from within the LITES network and will enroll approximately 750 injured adult patients who have suffered large 2nd or 3rd degree thermal burns on at least 20% of their body surface requiring burn resusciation. The objective is to determine if initiating plasma resuscitation as soon as possible upon arrival to an emergency department or burn unit is the most effective resuscitation for those who have experienced large thermal burns and significantly reduces the morbidity and mortality attributable to post-injury complications as compared to standard in-hospital resuscitation practice.

Eligibility criteria

Qualifiers

Estimated ≥ 20% Total Body Surface Area burn/thermal injury with 2nd or 3rd degree depth

Anticipated admission to burn ICU

Disqualifiers

Estimated rBaux score <55

Not expected to survive >24 hours

Wearing NO PREEVENT opt-out bracelet

Age > 75 or < 18 years of age

Trial design

Treatments tested in this trial

  • Plasma
  • Standard care

Treatment groups

750 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Jason Sperry

Lead sponsor

University of Pittsburgh

Sponsor institution

United States Department of Defense

Collaborator